Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Cyclophosphamide 23Temozolomide 14Filgrastim 13Irinotecan 12Melphalan 11Etoposide 10Carboplatin 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8X-Rays 7Topotecan 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Busulfan 7fludarabine 6Thiotepa 6Phantoms, Imaging 6fludarabine phosphate 5Radiotherapy 5Biopsy 5Antilymphocyte Serum 5Oxaliplatin 4Nuclear Medicine Department, Hospital 4Nivolumab 4Methylprednisolone 4Ifosfamide 4Cisplatin 4palbociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × robatumumab × Sarcoma × Clear all
NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Merck Sharp & Dohme LLC

Phase 1 Terminated
4 enrolled 8 charts
CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡